State lawmakers in Columbus spent Wednesday digging into a fresh flashpoint over abortion policy, hearing new backing for a proposal that would force Ohio doctors to read a state-written liability warning before prescribing mifepristone, the drug used in most medication abortions. Supporters told the Senate Health Committee the plan is about accountability and transparency, while physicians and rights groups countered that it piles on to existing informed-consent rules and risks corroding trust between patients and clinicians. The bill, Senate Bill 309, has drawn testimony from anti-abortion organizations and pregnancy resource centers and now sits in a Republican-led committee with its next move still unclear.
What the bill would do
S.B. 309, titled the Abortion Pill Provider Liability Education (APPLE) Act, would require a provider or the provider's agent to give patients written information listing "all known complications" of the abortion drug mifepristone, read a state-scripted warning aloud, and secure a signed certification to keep in the medical file, according to the Ohio Legislature. The measure would open the door to civil lawsuits and statutory penalties, including damages equal to three times the cost of the drug, and directs the Department of Health to design a standardized form that all providers would be required to use.
Who spoke in committee
Backers who showed up to testify were largely affiliated with anti-abortion groups and pregnancy resource centers, and they argued that a state-crafted notice would spell out risks more clearly for patients weighing a chemical abortion. "Informed consent is the ideal, but it is not happening, not consistently," Alyssa Thomas, medical manager for Pregnancy Decision Health Centers, told senators, according to the Ohio Capital Journal.
Opponents' concerns
Physicians and abortion-rights advocates pushed back, warning that the bill would duplicate informed-consent practices that are already required and could undermine the doctor-patient relationship. Democrats and other critics also highlighted that the proposal zeroes in on mifepristone while leaving other higher-risk medications alone. Sen. Beth Liston said she views "mifepristone as a widely used medication with lots of safety data behind it," in comments reported by the Springfield News-Sun.
Where the numbers stand
The Ohio Department of Health recorded 21,829 induced abortions in 2024 and 196 post-abortion care reports documenting complications, a rate under 1% of procedures. Lawmakers cited those figures while questioning witnesses, according to the Ohio Capital Journal. Supporters pointed to the post-abortion reports and concerns about adverse events as evidence that more state oversight is warranted, while opponents argued the data show serious complications from mifepristone are comparatively rare.
Legal questions
Some Democrats raised constitutional red flags, warning that singling out one medication could clash with the state reproductive-rights amendment that voters approved in 2023 and set up a court fight if the bill becomes law. Critics told senators that the narrow focus on mifepristone and the civil-liability provisions leave key procedural issues unresolved and make the measure a likely target for litigation, a concern noted in local coverage by the Springfield News-Sun.
Next steps and outlook
The bill lists Sen. Kyle Koehler as sponsor and names Sen. Jerry Cirino, Sen. Stephen Huffman, Sen. Susan Manchester and Sen. Kristina Roegner as cosponsors, and it remains in the Senate Health Committee, according to the Ohio Legislature. Republicans hold majorities in both chambers of the 136th General Assembly, a power balance that supporters say gives the measure a favorable path through committee and onto the floor, as noted by the ACLU of Ohio.
What to watch next: whether the Health Committee schedules a vote or proposes amendments, and whether the Department of Health begins drafting the standardized form the bill would require providers to use. If the measure advances, the fight is likely to shift from the hearing room to courtroom challenges and deeper scrutiny from the medical community.
.jpg){kind=link}